RxDoctor Payments Data

Leon Hendley, MD

Cardiovascular Disease · Vero Beach, FLNPI 1043213291

Payments from drug & device makers

$9,721in general payments, 2019–2025

Across 395 payments — averaging $24.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Boston Scientific$824
  • Pfizer$675
  • Bayer$670
  • AstraZeneca$665
  • Johnson & Johnson$517
  • plus $5K from 34 others

What the payments were for

  • Travel & lodging$4064%
  • Food & beverage$9,07293%
  • Education$1982%
  • Other$450%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,721 in reported general payments places this provider in the 70th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$450,436
Medicare patients
741
Services billed
3,459

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban416$368,009
XareltoRivaroxaban167$151,145
EntrestoSacubitril/Valsartan83$63,814
MultaqDronedarone Hcl12$28,507
MounjaroTirzepatide17$18,470
Repatha SureclickEvolocumab11$18,360
JardianceEmpagliflozin21$16,661
WegovySemaglutide12$15,283
OzempicSemaglutide16$14,780
FarxigaDapagliflozin Propanediol16$13,501
Metoprolol Succinate856$12,119
LivaloPitavastatin Calcium14$10,925
EdarbiAzilsartan Medoxomil27$8,875
VerquvoVericiguat12$7,950
Nebivolol Hcl80$6,053

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$675$368,009416 claims
Johnson & JohnsonXarelto$517$151,145167 claims
NovartisEntresto$1,173$63,81483 claims
Novo NordiskWegovy, Ozempic$237$30,06428 claims
Sanofi-aventis U.S. LLCMultaq$367$28,50712 claims
Boehringer IngelheimJardiance$516$16,66121 claims
AstraZenecaFarxiga$665$13,50116 claims
MerckVerquvo, Janumet Xr$226$13,30424 claims
Kowa Pharmaceuticals America, Inc.Livalo$322$10,92514 claims
Arbor Pharmaceuticals, Inc.Edarbi$113$8,87527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Vero Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →